Cetera Trust Company N.A Makes New Investment in Thermo Fisher Scientific Inc. $TMO

Cetera Trust Company N.A purchased a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO) during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 4,511 shares of the medical research company’s stock, valued at approximately $2,262,000. Thermo Fisher Scientific accounts for about 1.1% of Cetera Trust Company N.A’s investment portfolio, making the stock its 24th biggest holding.

Several other large investors have also modified their holdings of TMO. Elyxium Wealth LLC lifted its position in Thermo Fisher Scientific by 1.9% during the 4th quarter. Elyxium Wealth LLC now owns 1,058 shares of the medical research company’s stock worth $613,000 after acquiring an additional 20 shares during the last quarter. Revolve Wealth Partners LLC increased its stake in shares of Thermo Fisher Scientific by 4.2% in the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock worth $255,000 after purchasing an additional 20 shares during the period. Holt Capital Advisors L.L.C. dba Holt Capital Partners L.P. lifted its position in shares of Thermo Fisher Scientific by 0.7% during the 3rd quarter. Holt Capital Advisors L.L.C. dba Holt Capital Partners L.P. now owns 2,960 shares of the medical research company’s stock worth $1,436,000 after purchasing an additional 20 shares during the last quarter. Canandaigua National Trust Co of Florida increased its position in Thermo Fisher Scientific by 3.0% in the 4th quarter. Canandaigua National Trust Co of Florida now owns 765 shares of the medical research company’s stock worth $443,000 after buying an additional 22 shares during the period. Finally, Princeton Capital Management LLC boosted its position in shares of Thermo Fisher Scientific by 2.4% in the fourth quarter. Princeton Capital Management LLC now owns 922 shares of the medical research company’s stock valued at $534,000 after acquiring an additional 22 shares during the period. 89.23% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on TMO shares. Piper Sandler boosted their target price on shares of Thermo Fisher Scientific from $510.00 to $600.00 and gave the stock a “neutral” rating in a research report on Monday, July 27th. Royal Bank Of Canada raised their price target on shares of Thermo Fisher Scientific from $490.00 to $580.00 and gave the stock a “sector perform” rating in a research report on Friday, July 24th. Evercore set a $570.00 price objective on shares of Thermo Fisher Scientific in a research report on Monday, July 6th. Barclays lifted their target price on Thermo Fisher Scientific from $625.00 to $650.00 and gave the stock an “overweight” rating in a research report on Friday, July 24th. Finally, Morgan Stanley upped their price target on Thermo Fisher Scientific from $620.00 to $650.00 and gave the company an “overweight” rating in a report on Friday, July 24th. One research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $619.41.

Thermo Fisher Scientific Trading Down 0.1%

Shares of TMO stock opened at $628.69 on Tuesday. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.18 and a current ratio of 1.55. The firm has a fifty day moving average of $545.64 and a 200-day moving average of $509.60. Thermo Fisher Scientific Inc. has a 52-week low of $435.27 and a 52-week high of $643.99. The stock has a market cap of $232.46 billion, a price-to-earnings ratio of 33.82, a P/E/G ratio of 2.56 and a beta of 0.85.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share for the quarter, beating analysts’ consensus estimates of $5.71 by $0.32. The business had revenue of $11.99 billion for the quarter, compared to analysts’ expectations of $11.71 billion. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The firm’s revenue for the quarter was up 10.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $4.28 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. On average, equities research analysts forecast that Thermo Fisher Scientific Inc. will post 25.12 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, October 15th. Investors of record on Tuesday, September 15th will be given a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a dividend yield of 0.3%. The ex-dividend date is Tuesday, September 15th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.11%.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CAO Joseph R. Holmes sold 420 shares of the stock in a transaction on Friday, August 7th. The stock was sold at an average price of $584.81, for a total transaction of $245,620.20. Following the completion of the transaction, the chief accounting officer directly owned 2,966 shares in the company, valued at $1,734,546.46. This represents a 12.40% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Michael D. Shafer sold 25,500 shares of the business’s stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $600.00, for a total transaction of $15,300,000.00. Following the completion of the sale, the executive vice president owned 20,994 shares in the company, valued at $12,596,400. This represents a 54.85% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 73,493 shares of company stock valued at $43,950,381. 0.33% of the stock is owned by insiders.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.